Therapeutic Momentum – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Therapeutic Momentum

Science

Business

Frequency: 1 episode/90d. Total Eps: 8

The Therapeutic Momentum podcast series illuminates the inspiring personal stories, touchstone moments, and transformational events that fuel the relentless pursuit of life-changing treatments. It reveals the intricate tapestry of experiences that drive people in the biomedical field who share the collective goal of improving patient outcomes. We hope to offer listeners a multifaceted perspective on the diverse talent and backgrounds of people working towards better health and hope for patients.

Read moreCollapse

Site

RSS

Apple

Data updated on 14/07/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://www.robertplenge.com
2 shares

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 38%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal

Episode 7

Saturday, May 16, 2026 • Duration 53:38

In this episode I am joined by Kate Haviland, who most recently served as President and CEO of Blueprint Medicines, guiding it from a clinical-stage company through a fully integrated commercial business and ultimately through its roughly $9.5 billion acquisition by Sanofi in 2025. Over a more than twenty-year career spanning Genzyme, PTC Therapeutics, Sarepta, Idera, and Blueprint, Kate has built a reputation for bridging rigorous science with sharp business instincts, equally fluent in the lab and the boardroom. She studied biochemistry and economics at Wesleyan, earned her MBA at Harvard Business School, and today serves as Board Chair of both Fulcrum Therapeutics and GC Therapeutics, as a director at Bicara and Avalyn, and on the board of BIO. This episode was recorded in 2025

Read moreCollapse

AI + Life Sciences: Why the Future Needs Both Human Brains and Wet Labs

Saturday, April 11, 2026 • Duration 57:34

In this episode, I speak with Sam Scarpino, Director of AI and Life Sciences at Northeastern University's Institute for Experiential AI and Professor of Public Health and Health Sciences. With a background spanning evolutionary biology, pandemic response during H1N1, and pathogen surveillance at the Rockefeller Foundation, Sam offers a distinctive perspective on artificial intelligence in the life sciences.

We discuss the fundamental limitations of AI in biological systems, the irreplaceable role of wet lab experimentation, and how human-AI collaboration can address challenges from rural oncology access to rare disease drug development. Sam also shares his views on why current debates around AGI distract from the urgent work of building responsible AI tools today.

Read moreCollapse

Robert Plenge - Finding Truth & Making Medicines

Episode 6

Monday, January 19, 2026 • Duration 59:34

Robert Plenge is a physician-scientist known for his work at Merck, Celgene, and BMS, translating insights from human genetics into breakthroughs in drug discovery and development, resulting in new medicines. On his well-known blog, he writes with inspiring clarity about genomics, therapeutic target validation, and lessons from translational research, bridging academic rigor and industry practice for scientists and clinicians alike. In this interview, we explore Robert's passion for causal human biology, drug development, and leading teams.

Roberts Blog: https://www.robertplenge.com

Read moreCollapse

Dame Kate Bingham - Vision & Ventures

Episode 4

Thursday, July 31, 2025 • Duration 44:15

Dame Catherine Elizabeth "Kate" Bingham is a British biochemist and life‑sciences venture capitalist. She earned a first‑class MA in Biochemistry from Oxford and an MBA (Baker Scholar) from Harvard. Since 1991, she has been a managing partner at SV Health Investors, co‑founding the Dementia Discovery Fund and helping launch multiple first‑in‑class drugs. In May 2020, she chaired the UK’s Vaccine Taskforce, securing 350 million COVID‑19 doses and leading the country to be the first Western nation to begin vaccinations. Honored as a DBE in 2021, Kate also serves on the Francis Crick Institute and ARIA boards.

Read moreCollapse

Mathai Mammen - Motivated by Math, Medicine & Memories

Episode 3

Sunday, July 20, 2025 • Duration 01:08:24

Mathai Mammen is a world-renowned innovator in drug discovery, development, and team- and company-building responsible for creating 13 transformational medicines from discovery through commercial launch and more than 25 other potential medicines that have achieved clinical proof-of-concept, many of these practice-changing. Mathai is the CEO, President and Chairman of Cambridge-based Parabilis Medicines, a clinical-stage biopharmaceutical company advancing a new category of peptide therapeutics for people affected by cancer and other severe diseases. Previously Mathai was Executive Vice President of Pharmaceuticals, R&D at Johnson & Johnson, one of the largest R&D organizations in the world. Prior to that Mathai was the leader of much of the research at Merck including Oncology, Immunology and Cardiovascular Disease. He began his career as head of R&D at Theravance, Inc., a company he co-founded out of graduate school based on his work at Harvard University with Dr. George Whitesides, which split to form Theravance Biopharma and Innoviva. Mathai holds an M.D. from the Harvard Medical School and Massachusetts Institute of Technology (HST) and a Ph.D. in chemistry from Harvard University.

Read moreCollapse

Rupert Vessey: Leading Life Science Innovators

Episode 2

Saturday, July 19, 2025 • Duration 55:45

Read moreCollapse

Andy Plump - Translational Roles & Global Perspectives

Episode 1

Friday, July 18, 2025 • Duration 44:45

Andy Plump discusses his journey from a postdoc at UCSF to a leading roles in pharmaceutical research. Andy, who joined Merck in 2001, worked in clinical pharmacology. He highlighted the importance of genetics in target selection and shares his experiences at Sanofi and Takeda, emphasizing the cultural sensitivities and leadership lessons gained from global experiences. The interview explores the transformative potential of AI and machine learning in biopharmaceutical research.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

Read moreCollapse

Cholesterol Wars - Battling the Number One Killer

Episode 5

Monday, June 30, 2025 • Duration 13:27

Coronary heart disease is no longer a mystery. Listen to the story of one of medicine’s greatest triumphs — a battle fought in labs, clinics, kitchens, and boardrooms. This is the story of cholesterol. And how we turned a silent killer into a preventable disease.

Read moreCollapse

Therapeutic Momentum – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Therapeutic Momentum – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Other1

Apple Podcasts

Spotify